Description
DBPR108 is a potent, selective, orally bioavailable and long-acting inhibitor of DPP4 with IC50 of 15nM, >3,000-fold selectivity over DPP8, DPP9, FAP and DPP-II; exhibits excellent human plasma DPP-IV inhibition with IC50 of 5nM, suppresses blood glucose elevation in vivo, demonstrates potential treatment of type 2 diabetes mellitus. Diabetes Phase 1 Clinical